Deboever Nathaniel, Mitchell Kyle G, Feldman Hope A, Cascone Tina, Sepesi Boris
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2022 Feb 28;14(5):1263. doi: 10.3390/cancers14051263.
With recent strides made within the field of thoracic oncology, the management of NSCLC is evolving rapidly. Careful patient selection and timing of multi-modality therapy to permit the optimization of therapeutic benefit must be pursued. While chemotherapy and radiotherapy continue to have a role in the management of lung cancer, surgical therapy remains an essential component of lung cancer treatment in early, locally and regionally advanced, as well as in selected, cases of metastatic disease. Recent and most impactful advances in the treatment of lung cancer relate to the advent of immunotherapy and targeted therapy, molecular profiling, and predictive biomarker discovery. Many of these systemic therapies are a part of the standard of care in metastatic NSCLC, and their indications are expanding towards surgically operable lung cancer to improve survival outcomes. Numerous completed and ongoing clinical trials in the surgically operable NSCLC speak to the interest and importance of the multi-modality therapy even in earlier stages of NSCLC. In this review, we focus on the current standard of care indications for surgical therapy in stage I-IV NSCLC as well as on the anticipated future direction of multi-disciplinary lung cancer therapy.
随着胸科肿瘤学领域最近取得的进展，非小细胞肺癌（NSCLC）的管理正在迅速演变。必须谨慎选择患者并确定多模式治疗的时机，以实现治疗效益的优化。虽然化疗和放疗在肺癌管理中仍发挥作用，但手术治疗仍然是早期、局部和区域晚期以及部分转移性疾病病例中肺癌治疗的重要组成部分。肺癌治疗中最近且最具影响力的进展与免疫疗法和靶向疗法的出现、分子谱分析以及预测性生物标志物的发现有关。这些全身治疗方法中的许多都是转移性NSCLC标准治疗的一部分，其适应症正在向可手术切除的肺癌扩展，以改善生存结果。在可手术切除的NSCLC中，许多已完成和正在进行的临床试验表明，即使在NSCLC的早期阶段，多模式治疗也备受关注且至关重要。在本综述中，我们重点关注I-IV期NSCLC手术治疗的当前标准治疗适应症以及多学科肺癌治疗的预期未来方向。
